lenalidomide has been researched along with Neuroblastoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodeur, GM; Calonghi, N; Chorny, M; Farruggia, G; Guan, P; Kolla, V; Nguyen, F; Orienti, I | 2 |
| Bybjerg-Grauholm, J; Hansen, LL; Machaliński, B; Paczkowska, E; Pastuszak, K; Sokolowska, KE; Supernat, A; Taryma-Lesniak, O; Wojdacz, TK; Łuczkowska, K | 1 |
| Asgharzadeh, S; Liu, WY; Seeger, RC; Sheard, MA; Sposto, R; Sun, J; Tran, HC; Wan, Z; Wu, HW; Xu, Y | 1 |
4 other study(ies) available for lenalidomide and Neuroblastoma
| Article | Year |
|---|---|
A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Stability; Female; Fenretinide; Humans; Injections, Subcutaneous; Lenalidomide; Mice; Mice, Nude; Micelles; Nanoparticles; Neuroblastoma; Xenograft Model Antitumor Assays | 2019 |
Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Delivery Systems; Female; Fenretinide; Gene Expression Regulation, Neoplastic; Humans; Killer Cells, Natural; Lenalidomide; Mice, Nude; Micelles; Microscopy, Confocal; N-Myc Proto-Oncogene Protein; Nanostructures; Neuroblastoma; Xenograft Model Antitumor Assays | 2020 |
Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Neuroblastoma | 2021 |
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Culture Media, Conditioned; Female; Humans; Interleukin-6; Killer Cells, Natural; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Thalidomide; Transforming Growth Factor beta1; Tumor Microenvironment | 2013 |